verezdoВестник репродуктивного здоровьяBulletin of Reproductive Health2075-65692310-421XEndocrinology Research Centre (Moscow)10.14341/brh200916-14verezdo-8544Research ArticleСтатьиArticlesПредиабет: современные критерии диагностики и перспективы леченияPrediabet: sovremennye kriterii diagnostiki i perspektivy lecheniyaКалашниковаМ ФKalashnikovaM F-БуденнаяИ ЮBudennayaI Yu-УчампринаВ АUchamprinaV A-ММА им. И.М. Сеченова20091503200901№1 (2009)614Copyright © Калашникова М.Ф., Буденная И.Ю., Учамприна В.А., 20092009Калашникова М.Ф., Буденная И.Ю., Учамприна В.А.Kalashnikova M.F., Budennaya I.Y., Uchamprina V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.vrz-endojournals.ru/jour/article/view/8544

Прогрессивный рост числа больных сахарным диабетом (СД) представляет серьезную угрозу для всего населения и является одной из ведущих медико-социальных проблем здравоохранения. Около 75–80% лиц с СД умирают от сердечно-сосудистых заболеваний (ССЗ). У людей с СД 2 типа риск ишемической болезни сердца (ИБС) в 2–4 раза выше, чем у остальных в популяции. Риск цереброваскулярных и периферических сосудистых заболеваний также значительно выше. Преждевременная смертность, вызванная СД, приводит к предполагаемому сокращению жизни на12–14 лет. Эффективная первичная профилактика СД, направленная на предотвращение развития заболевания — наиболее рациональный путь, позволяющий увеличить продолжительность жизни пациентов, улучшить их качество жизни и снизить социально-экономические затраты.В последние годы во всем мире принимаются меры для определения стратегий по предотвращению развития и увеличению сроков клинической манифестации СД 2 типа. Клинические исследования наглядно демонстрируют, что превентивные программы могут значительно снизить риск развития заболевания.

ReferencesAlberti K. The clinical implications of impared glucose tolerance. Diab Metab 2002; 19: 708–723.Alberti K. The clinical implications of impared glucose tolerance. Diab Metab 2002; 19: 708–723.World Health Organization, International Diabetes Fed-eration. Definition and diagnosis of diabetes mellitus and intermedi-ate hyperglycemia: report of a WHO/IDF consultation. Available at: http:// www.who.int/diabetes/publications/Definitions%20and%20diagnosis%20 of%20diabetes_new.pdf. Accessed November 5, 2007.World Health Organization, International Diabetes Fed-eration. Definition and diagnosis of diabetes mellitus and intermedi-ate hyperglycemia: report of a WHO/IDF consultation. Available at: http:// www.who.int/diabetes/publications/Definitions%20and%20diagnosis%20 of%20diabetes_new.pdf. Accessed November 5, 2007.Guidelines on Diabetes, Pre-diabetes, and Cardiovascu-lar Diseases. Eur Heart J 2007; 9: 1–74.Guidelines on Diabetes, Pre-diabetes, and Cardiovascu-lar Diseases. Eur Heart J 2007; 9: 1–74.Alberti K.G.M.M., Zimmet P., Shaw J. International Dia-betes Federation: a consensus on Type 2 diabetes prevention. Dia-bet Med 2007; 24: 451–463.Alberti K.G.M.M., Zimmet P., Shaw J. International Dia-betes Federation: a consensus on Type 2 diabetes prevention. Dia-bet Med 2007; 24: 451–463.Centers for disease control. Number of people with dia-betes increases to 24 million. http://www.cdc.gov/media/pressrel/2008/r080624. htm. Posted June 24, 2008. Accessed July 21, 2008.Centers for disease control. Number of people with dia-betes increases to 24 million. http://www.cdc.gov/media/pressrel/2008/r080624. htm. Posted June 24, 2008. Accessed July 21, 2008.Diabetes Association. Diabetes and classification of dia-betes mellitus. Diabetes care 2004; 27 (Suppl.1): S5—S10.Diabetes Association. Diabetes and classification of dia-betes mellitus. Diabetes care 2004; 27 (Suppl.1): S5—S10.International Diabetes Federation. Diabetes Atlas: Prevalence. http:// www.eatlas.idf.org/Prevalence. Accessed August 1, 2008.International Diabetes Federation. Diabetes Atlas: Prevalence. http:// www.eatlas.idf.org/Prevalence. Accessed August 1, 2008.Дедов И.И., чазова Т.Е., Сунцов Ю.И. Эпидемиология сахарного диабета. М: Медицина для Вас 2003: 47—51.Дедов И.И., чазова Т.Е., Сунцов Ю.И. Эпидемиология сахарного диабета. М: Медицина для Вас 2003: 47—51.Valensi P., Schwarz P.E.N., Hall M. et al. Pre-diabetes essential action: a European perspective. Diabet Metab 2005; 31: 606–620.Valensi P., Schwarz P.E.N., Hall M. et al. Pre-diabetes essential action: a European perspective. Diabet Metab 2005; 31: 606–620.Uusitupa M., Lindi V., Louheranta A. et al. for the Finnish Diabetes Prevention Study Group. Long-Term Improvement in Insu-lin Sensitivity by Changing Lifestyles of People with Impared Glu-cose Tolerance. Diabetes 2003; 52: 2532–2538.Uusitupa M., Lindi V., Louheranta A. et al. for the Finnish Diabetes Prevention Study Group. Long-Term Improvement in Insu-lin Sensitivity by Changing Lifestyles of People with Impared Glu-cose Tolerance. Diabetes 2003; 52: 2532–2538.Targerson J.S., Hauptman J., Bolrin M.N., Sjostrom L. XENikal in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155–161.Targerson J.S., Hauptman J., Bolrin M.N., Sjostrom L. XENikal in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155–161.Chiasson J.L., Josse R.G., Gomis R. et al. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486—494.Chiasson J.L., Josse R.G., Gomis R. et al. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486—494.Diabetes Prevention Research Group: Reduction in the evidence of type 2 diabetes with life-style intervention or metformin. New Engl J Med 2002; 346: 393–403.Diabetes Prevention Research Group: Reduction in the evidence of type 2 diabetes with life-style intervention or metformin. New Engl J Med 2002; 346: 393–403.Pan X.R., Li G.W., Hu Yh., et al. Effects of diet and ex-ercise in preventing NIDDM in people with impaired glucose toler-ance: the Da Qing IGT and Diabetes Study. Diabetes care 1997; 20: 537–544.Pan X.R., Li G.W., Hu Yh., et al. Effects of diet and ex-ercise in preventing NIDDM in people with impaired glucose toler-ance: the Da Qing IGT and Diabetes Study. Diabetes care 1997; 20: 537–544.Vegt F. de, Dekker Jm., Jager A. et al. Relation of im-pared fasting andpostload glucose with incident Type 2 diabetes in a Dutch population: the Hoorn Study. JAMA 2001; 285: 2109–2113.Vegt F. de, Dekker Jm., Jager A. et al. Relation of im-pared fasting andpostload glucose with incident Type 2 diabetes in a Dutch population: the Hoorn Study. JAMA 2001; 285: 2109–2113.Haffner S.M., Mykkanen L., Festa A. et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulinsensitive prediabetic subjects: implication for preventing coronary heart disease during the prediabetic state. Circulation 2000; 101: 975–980.Haffner S.M., Mykkanen L., Festa A. et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulinsensitive prediabetic subjects: implication for preventing coronary heart disease during the prediabetic state. Circulation 2000; 101: 975–980.The DECODE Study Group: Glucose tolerance and car-diovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397–405The DECODE Study Group: Glucose tolerance and car-diovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397–405Wilson P.W., D’Agostino R.B., Parise H. et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 dia-betes mellitus. Circulation 2005; 112:3066–3072.Wilson P.W., D’Agostino R.B., Parise H. et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 dia-betes mellitus. Circulation 2005; 112:3066–3072.Pre-diabetes consensus statement. Endocr Pract 2008; 14: 935– 942.Pre-diabetes consensus statement. Endocr Pract 2008; 14: 935– 942.Jean-Louis Chiasson. Prevention of type 2 diabetes: fact or fiction? Expert Opinion on Pharmacotherapy. 2007: 3147–3158.Jean-Louis Chiasson. Prevention of type 2 diabetes: fact or fiction? Expert Opinion on Pharmacotherapy. 2007: 3147–3158.Valensi P., Eschwege E., Thomas D. et al. Prevalence of unknown diabetes in France: Targeted screening by General Practi-tioners according to the ANAES Recommendations. First Interna-tional Congress on «Prediabetes and Metabolic Syndrome». Berlin 2005.Valensi P., Eschwege E., Thomas D. et al. Prevalence of unknown diabetes in France: Targeted screening by General Practi-tioners according to the ANAES Recommendations. First Interna-tional Congress on «Prediabetes and Metabolic Syndrome». Berlin 2005.Dixon J.B., O’Brien P.E., Playfair J. et al. Adjustable gas-tric Banding and conventional therapy for tupe 2 diabetes: a ran-domized controlled trial. JAMA 2008; 299: 316–323.Dixon J.B., O’Brien P.E., Playfair J. et al. Adjustable gas-tric Banding and conventional therapy for tupe 2 diabetes: a ran-domized controlled trial. JAMA 2008; 299: 316–323.McNulty S.J., Ur E., Williams G.; Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003; 26: 125–131.McNulty S.J., Ur E., Williams G.; Multicenter Sibutramine Study Group. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003; 26: 125–131.Garber A.J., Handelsman Y., Einhorn D. et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia — when do the risks of diabetes begin? A consensus statement from the American college of endocrinology and the American as-sociation of clinical endocrinologists. Endocrine practice. 2008; 14(7): 933–945.Garber A.J., Handelsman Y., Einhorn D. et al. Diagnosis and management of prediabetes in the continuum of hyperglycemia — when do the risks of diabetes begin? A consensus statement from the American college of endocrinology and the American as-sociation of clinical endocrinologists. Endocrine practice. 2008; 14(7): 933–945.Bailey C.J., Turner R.C. Metformin. New Eng J Med 1996; 334: 574– 579.Bailey C.J., Turner R.C. Metformin. New Eng J Med 1996; 334: 574– 579.Ramachandran Aю, Snehalatha Cю, Yamuna A. Cost-Effectiveness of the Interventions in the Primary Prevention of Diabetes Among Asian Indians Within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care 2007; 30: 2548–2552.Ramachandran Aю, Snehalatha Cю, Yamuna A. Cost-Effectiveness of the Interventions in the Primary Prevention of Diabetes Among Asian Indians Within-trial results of the Indian Diabetes Prevention Programme (IDPP). Diabetes Care 2007; 30: 2548–2552.Nathan D.M., Davidson M.B., deFronzo R.A. et al. Im-paired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30: 753–759.Nathan D.M., Davidson M.B., deFronzo R.A. et al. Im-paired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30: 753–759.DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators, Gertein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabe-tes in patients with imparedglucose tolerance or impared fasting glucose: a randomized controlled trial Lancet 2006; 368: 1096–1105.DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators, Gertein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabe-tes in patients with imparedglucose tolerance or impared fasting glucose: a randomized controlled trial Lancet 2006; 368: 1096–1105.Davidson M.B. Clinical Implications of the DREAM Study: should prediabetes be treated to prevent diabetes or heart disease. Available at: http://www.natap.org/2007/HIV/022307_01.htm.Davidson M.B. Clinical Implications of the DREAM Study: should prediabetes be treated to prevent diabetes or heart disease. Available at: http://www.natap.org/2007/HIV/022307_01.htm.American Diabetes Association: Position Statement: Management of Dyslipidemia in Adults With Diabetes. Diabetes Care 2003; 26: 83–86.American Diabetes Association: Position Statement: Management of Dyslipidemia in Adults With Diabetes. Diabetes Care 2003; 26: 83–86.Summury of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.Summury of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.Endocrine Society. Primary prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: Clinical Practice Guidline. J Clin Endocrinol Metab 2008; 93(10): 3671–3689.Endocrine Society. Primary prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk: Clinical Practice Guidline. J Clin Endocrinol Metab 2008; 93(10): 3671–3689.Schwarz P.E.H. et al. European perspective of Diabetes Prevention. Hormon Metabol Res 2008; 40: 511–514.Schwarz P.E.H. et al. European perspective of Diabetes Prevention. Hormon Metabol Res 2008; 40: 511–514.

The authors declare that there are no conflicts of interest present.